• Treatment of opioid-induced constipation in patients with chronic noncancer pain, including those with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.

Contraindicated in:

• Hypersensitivity
• Known/suspected mechanical GI obstruction
• ↑ risk of recurrent GI obstruction
• Severe hepatic impairment
• Lactation: Lactation.

Use Cautiously in:

• Known/suspected lesions of GI tract (↑ risk for GI perforation)
• Receiving opioids for <4 wk (may be less responsive to naldemedine)
• OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk
• Pedi: Safety and effectiveness not established in children.

GI: abdominal pain, diarrhea, gastroenteritis, GI PERFORATION, nausea, vomiting.
Misc: opioid withdrawal.

Drug-Drug:

• Strong CYP3A inducers, including carbamazepine, phenytoin, or rifampin, may ↓ levels and effectiveness; avoid concurrent use.
• Other opioid antagonists may cause additive effects and ↑ risk of opioid withdrawal.
• Moderate CYP3A inhibitors and strong CYP3A inhibitors, including aprepitant, atazanavir, clarithromycin, diltiazem, erythromycin, fluconazole, itraconazole, ketoconazole, or ritonavir, may ↑ levels and risk of toxicity.
• P-glycoprotein inhibitors, including amiodarone, captopril, cyclosporine, quinidine, or verapamil, may ↑ levels and risk of toxicity.

Drug-Natural Products:

• St. John's wort may ↓ levels and its effectiveness; avoid concurrent use.

• Tablets: 0.2 mg;

• PO (Adults): 0.2 mg once daily.

Symproic

• Acts peripherally as a mu-opioid receptor antagonist, blocking opioid effects on the GI tract.

• Blocks constipating effects of opioids on the GI tract without loss of analgesia.

Therapeutic Classification: laxatives

Pharmacologic Classification: opioid antagonists

Absorption: Rapidly absorbed; absorption delayed by high-fat meal by 2 hr.

Distribution: Moderate tissue distribution, does not cross the blood-brain barrier.

Protein Binding: 93–94%.

Metabolism/Excretion: Primarily metabolized by liver via the CYP3A isoenzyme to an active metabolite (nor-naldemedine); 57% excreted in urine (16–18% as unchanged drug), 35% excreted in feces.

Half-life: 11 hr.

(plasma concentrations)

• Instruct patient to take naldemedine as directed. Advise patient to read Medication Guide prior to starting therapy and with each refill in case of changes.
• Advise patient to notify health care professional immediately if stomach pain that does not go away occurs.
• Advise patient to notify health care professional if signs and symptoms of opioid withdrawal (sweating, chills, diarrhea, stomach pain, anxiety, irritability, yawning) occur. Patients taking methadone for pain are at increased risk for stomach pain and diarrhea.
• Instruct patient to stop taking naldemedine if they stop taking opioid medications.
• Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
• Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected and to avoid breastfeeding during and for 3 days after last dose of therapy.

nal-DEM-e-deen